Related Experiment Video
Updated: Sep 26, 2026
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Editor's Choice- Pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome
Xavier Rossello1,2, Manuel Lobo-Gonzalez1, Borja Ibanez1,2,3
11 Translational Laboratory for Cardiovascular Imaging and Therapy, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Spain.
Insights
Reducing injury in ST-segment elevation myocardial infarction (STEMI) requires interventions beyond reperfusion. This review explores cardioprotective therapies, including mechanical and pharmacological approaches, to minimize infarct size and improve patient outcomes.
Area of Science:
- Cardiology
- Translational Medicine
- Pharmacology
Background:
- ST-segment elevation myocardial infarction (STEMI) causes significant injury, even after timely reperfusion.
- Ischaemia/reperfusion syndrome involves complex interactions between cardiomyocytes, microcirculation, and circulating cells.
- Current treatments aim to limit infarct size, but further interventions are needed.
Purpose of the Study:
- To review the clinical impact and pathophysiology of STEMI.
- To summarize existing and novel cardioprotective therapies for reducing infarct size.
- To highlight future directions for clinical trials and patient selection.
Main Methods:
- Comprehensive literature review of epidemiological, clinical, and biological data on STEMI.
- Analysis of the pathophysiology of ischaemia/reperfusion injury.
- Evaluation of mechanical (ischaemic conditioning) and pharmacological interventions (metoprolol, exenatide, N-acetylcysteine).
Main Results:
- Review covers STEMI's clinical impact, pathophysiology, and cardioprotective strategies.
- Discusses both successful and unsuccessful therapeutic interventions.
- Identifies novel targets for ameliorating ischaemia/reperfusion injury.
Conclusions:
- Effective cardioprotection in STEMI requires interventions beyond reperfusion.
- Further research into mechanical and pharmacological therapies is crucial.
- Improved clinical trial design and patient selection are necessary for advancing cardioprotective strategies.
Abstract:
There is a need to find interventions able to reduce the extent of injury in reperfused ST-segment elevation myocardial infarction (STEMI) beyond timely reperfusion. In this review, we summarise the clinical impact of STEMI from epidemiological, clinical and biological perspectives. We also revise the pathophysiology underlying the ischaemia/reperfusion syndrome occurring in reperfused STEMI, including the several players involved in this syndrome, such as cardiomyocytes, microcirculation and circulating cells. Interventions aimed to reduce the resultant infarct size, known as cardioprotective therapies, are extensively discussed, putting the focus on both mechanical interventions (i.e. ischaemic conditioning) and promising pharmacological therapies, such as early intravenous metoprolol, exenatide and other glucose modulators, N-acetylcysteine as well as on some other classic therapies which have failed to be translated to the clinical arena. Novel targets for evolving therapeutic interventions to ameliorate ischaemia/reperfusion injury are also discussed. Finally, we highlight the necessity to improve the study design of future randomised clinical trials in the field, as well as to select patients better who can most likely benefit from cardioprotective interventions.
Related Concept Videos
01:21Myocarditis I: Introduction
01:14Myocarditis III: Medical Management
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:15Ischemic Stroke ll: Pathophysiology